FDA Commissioner Marty Makary announced that Vinay Prasad will leave the agency in April after a tumultuous year marked by controversy. The decision comes after a series of self-destructive moves, including rejecting an mRNA vaccine over scientists' objections and demanding additional trials for a Huntington's disease gene therapy. His public attacks on biotech firm UniQure and alleged staff abuse created a toxic work environment.

Prasad's departure has been met with enthusiasm from the biotechnology sector. Financial analysts called it "a big win for biotech, especially for companies in the rare disease space," according to BioSpace. Several companies saw stock prices jump on Monday, with UniQure's shares leaping approximately 25 percent. This marks Prasad's second exit from the FDA during the current administration after he resigned in July over criticism from far-right activist Laura Loomer.

The controversy surrounding Prasad's tenure stems from his lack of regulatory experience and expertise in vaccines or gene therapies. Despite being a professor at UCSF and practicing hematology-oncologist, his rise to prominence came from online criticism of pandemic-era policies rather than scientific credentials in biologics regulation.